News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Aerocrine: Interim Report January - June 2011
July 22, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Sales for routine clinical use in the US continue to show a positive trend. Aerocrine (STO:AEROB) secured the company's largest single order to date, valued at SEK 5.5 million.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nations’ Proposal
May 8, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Gilead Pumps $11B More Into US Manufacturing, Hopes To Add 3,000 Jobs
May 8, 2025
·
2 min read
·
Tristan Manalac
Cancer
C4 Therapeutics Shelves BRAF Blocker, Goes All-In on Multiple Myeloma Drug
May 7, 2025
·
1 min read
·
Tristan Manalac
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
